...
首页> 外文期刊>OncoTargets and therapy >Salinomycin and Sulforaphane Exerted Synergistic Antiproliferative and Proapoptotic Effects on Colorectal Cancer Cells by Inhibiting the PI3K/Akt Signaling Pathway in vitro and in vivo
【24h】

Salinomycin and Sulforaphane Exerted Synergistic Antiproliferative and Proapoptotic Effects on Colorectal Cancer Cells by Inhibiting the PI3K/Akt Signaling Pathway in vitro and in vivo

机译:SALINOMYCIN和SULFORAPHAPHE通过在体外和体内抑制PI3K / AKT信号通路对结直肠癌细胞产生协同抗增殖和促凋亡效应

获取原文
           

摘要

Background: Both salinomycin (SAL) and sulforaphane (SFN) exert their antitumorigenic effects in various types of cancer We investigated whether combining salinomycin (SAL, an antibiotic ionophore) with sulforaphane (SFN, a phytochemical) exerted synergistic antiproliferative and proapoptotic activities in colorectal cancer (CRC) cells in vitro and in vivo by evaluating the proliferative and apoptotic responses of two CRC cell lines. Materials and Methods: The combination index (CI) was calculated using the Chou-Talalay method, and the effects of the synergistic combination (CI 1) of lower doses of SAL and SFN were selected for further studies. Anti-tumor effect of the combination of SAL and SFN was tested both in vitro and in vivo. Results: Cotreatment effectively inhibited proliferation, migration and invasion and enhanced apoptosis. The xenograft model also showed similar results. Furthermore, we evaluated the molecular mechanism behind SAL- and SFN-mediated CRC cell apoptosis. The combination treatment induced apoptosis in Caco-2 and CX-1 cells by inhibiting the PI3K/Akt pathway, which increased the expression of the tumor suppressor protein p53. The treatment also decreased the expression of the survival protein Bcl-2 and increased the expression of the proapoptotic protein Bax, which increased the Bax/Bcl-2 ratio, as well as enhanced poly ADP-ribose polymerase (PARP) cleavage. Upon inhibiting the PI3K/Akt pathway with LY294002 prior to cotreatment, we detected enhanced PARP cleavage compared to that in the cotreatment only group. Conclusion: We investigated whether the combination of SAL and SFN had antiproliferative and proapoptotic effects in CRC cells both in vitro and in vivo. Cotreatment also significantly decreased migration and invasion compared to that of the control and SAL or SFN monotherapies. This novel combination of SAL and SFN might provide a potential strategy to treat CRC.
机译:背景:Salinomycin(Sal)和Sulforaphane(SFN)在各种类型的癌症中发挥其抗肿瘤作用,我们研究了与亚磺霉素(SAL,抗生素离子载体)与亚磺霉素(SFN,植物化学)施加协同抗增殖和促凋亡活动在结肠直肠癌中(CRC)通过评估两种CRC细胞系的增殖和凋亡反应来体外和体内体内的细胞。材料和方法:使用Chou-talalay方法计算组合指数(CI),选择较低剂量的SAL和SFN的协同组合(CI <1)的效果进行进一步研究。在体外和体内测试Sal和SFN组合的抗肿瘤效应。结果:CoTreatment有效抑制增殖,迁移和侵袭和增强的细胞凋亡。异种移植模型也显示出类似的结果。此外,我们评估了SAL和SFN介导的CRC细胞凋亡背后的分子机制。通过抑制PI3K / AKT途径,组合治疗在Caco-2和CX-1细胞中诱导细胞凋亡,这增加了肿瘤抑制蛋白P53的表达。该处理还降低了存活蛋白Bcl-2的表达,并增加了促凋亡蛋白Bax的表达,其增加了Bax / Bcl-2的比例,以及增强的聚ADP-核糖聚合酶(PARP)切割。在抑制Cotreatment之前用Ly294002抑制pi3k / akt途径,我们检测到与Cotreatment中的基团相比,检测到增强的PARP切割。结论:我们研究了SAL和SFN的组合是否在体外和体内在CRC细胞中具有抗增殖和凋亡作用。与对照和SAL或SFN单疗法相比,CoTreatment也显着降低了迁移和侵袭。这种新的SAL和SFN组合可能提供治疗CRC的潜在策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号